News Related to Myrbetriq

Related coverage linked through entity extraction aliases.

Lupin Reports 26% Revenue Growth in Q3 FY26, Receives FDA Approval for Biosimilar Pegfilgrastim

Feb 24, 2026

Lupin Limited reported strong Q3 FY26 results with total sales of ₹71,005 million, up 26% year-over-year, and received US FDA approval for its pegfilgrastim biosimilar Armlupeg™, which has not yet been launched.

Zydus Settles Mirabegron Patent Dispute with Astellas for $120 Million

Feb 13, 2026

Zydus Lifesciences resolves US patent litigation with Astellas Pharma over generic Mirabegron for $120 million plus per-unit licensing fees through September 2027, enabling continued US marketing.